Skip to main content
Premium Trial:

Request an Annual Quote

FDA Allows Emergency Use of Applied BioCode, Kaiser Permanente, Emory University Coronavirus Tests

NEW YORK — The US Food and Drug Administration has granted separate Emergency Use Authorizations for SARS-CoV-2 tests from Applied BioCode, Kaiser Permanente, and Emory University.

Applied BioCode's SARS-CoV-2 Assay is designed to detect two conserved regions in the virus' N gene in upper respiratory specimens and bronchoalveolar lavage. Nucleic acids are extracted using BioMérieux's NucliSens EasyMag or Roche's MagNA Pure 96 automated systems and the test runs on Applied Biocode's MDx-3000 instrument. The assay may be performed by any lab CLIA-certified for high-complexity tests.

Kaiser Permanente's KPMAS COVID-19 Test comprises a home collection kit that is designed for the self-collection of a nasal swab sample by the healthcare plan's members. Samples are transported to Kaiser Permanente Mid-Atlantic States' regional laboratory in Rockville, Maryland for analysis with Roche's Cobas SARS-CoV-2 assay, which received Emergency Use Authorization in March.

Emory's SARS-CoV-2 RBD IgG test is an ELISA-based assay designed to detect immunoglobulin G antibodies against the virus in human serum in order to determine a recent or prior infection, according to the FDA. Use of the test is limited to Emory Medical Laboratories.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.